3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma
224
Lymphoma, Large B-Cell, Diffuse
160
Small Cell Lung Carcinoma
153
Precursor Cell Lymphoblastic Leukemia-Lymphoma
143
Lymphoma, Non-Hodgkin
139
Leukemia
135
Leukemia, Myeloid, Acute
117
Hodgkin Disease
106
Burkitt Lymphoma
99
Lung Neoplasms
98
Lymphoma, Follicular
85
Lymphoma, Mantle-Cell
76
Lymphoma, Large-Cell, Immunoblastic
68
Carcinoma, Non-Small-Cell Lung
61
Neuroblastoma
60
Leukemia, Lymphocytic, Chronic, B-Cell
56
Recurrence
53
Multiple Myeloma
52
Lymphoma, B-Cell, Marginal Zone
43
Congenital Abnormalities
43
Sarcoma
39
Central Nervous System Neoplasms
39
Myelodysplastic Syndromes
35
Brain Neoplasms
34
Ovarian Neoplasms
32
Leukemia, Myelomonocytic, Acute
32
Lymphoma, B-Cell
31
Leukemia, Monocytic, Acute
31
Leukemia, Erythroblastic, Acute
31
Testicular Neoplasms
30
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration-Resistant Prostate Cancer
×
Etoposide
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled